iRadimed (NASDAQ:IRMD – Get Free Report) and Ekso Bionics (NASDAQ:EKSO – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.
Earnings & Valuation
This table compares iRadimed and Ekso Bionics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iRadimed | $83.81 million | 14.19 | $22.48 million | $1.75 | 53.17 |
| Ekso Bionics | $12.80 million | 2.85 | -$11.69 million | ($5.14) | -2.00 |
Risk and Volatility
iRadimed has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Ekso Bionics has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for iRadimed and Ekso Bionics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
| Ekso Bionics | 1 | 1 | 0 | 0 | 1.50 |
iRadimed presently has a consensus price target of $120.00, indicating a potential upside of 28.96%. Ekso Bionics has a consensus price target of $6.00, indicating a potential downside of 41.52%. Given iRadimed’s stronger consensus rating and higher probable upside, equities analysts plainly believe iRadimed is more favorable than Ekso Bionics.
Insider and Institutional Ownership
92.3% of iRadimed shares are owned by institutional investors. Comparatively, 6.4% of Ekso Bionics shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 6.0% of Ekso Bionics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares iRadimed and Ekso Bionics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iRadimed | 26.82% | 23.83% | 20.83% |
| Ekso Bionics | -91.37% | -110.52% | -50.71% |
Summary
iRadimed beats Ekso Bionics on 15 of the 15 factors compared between the two stocks.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
About Ekso Bionics
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.
Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.
